Clinical Trials Arena on MSN21d
NiKang concludes first cohort dosing in Phase I trial of NKT3964 for tumours
NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for treating adults with advanced or metastatic solid tumours. The dose-escalation ...
C&EN5d
Antiviral unveiled that goes after multiple coronaviruses
This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.
FierceBiotech21d
Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader
The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study assessed vepdegestrant against AstraZeneca’s hormone med Faslodex in ...